載入...
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome
On August 30, 2017, the U.S. Food and Drug Administration approved Actemra (tocilizumab, Genentech, Inc., South San Francisco, CA) for the treatment of severe or life‐threatening chimeric antigen receptor (CAR) T cell‐induced cytokine release syndrome (CRS) in adults and in pediatric patients 2 year...
Na minha lista:
| 發表在: | Oncologist |
|---|---|
| Main Authors: | , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
AlphaMed Press
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6156173/ https://ncbi.nlm.nih.gov/pubmed/29622697 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0028 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|